Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 11;82(11):1404–1414. doi: 10.1136/ard-2023-224431

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

PASI responders to Week 52. Randomised set, in patients with psoriasis affecting ≥3% BSA at baseline. P value was calculated using a logistic regression model with treatment, bone erosion at baseline and region as stratification factors. The study was not powered for statistical comparisons of ADA with BKZ or PBO. All data points can be found in table format in online supplemental table 6. *PASI90 was a ranked secondary end point. ADA, adalimumab; BKZ, bimekizumab; BSA, body surface area; NRI, non-responder imputation; OC, observed case; PASI75/90/100, Psoriasis Area and Severity Index ≥75%/90%/100% improvement; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks.